Shares of Eupraxia Pharmaceuticals surged 10.6% to $9.00 on September 24 after two analyst upgrades converged on the same thesis: the company's experimental injection for a painful swallowing disorder could carve out a meaningful niche in a fast-growing market. Stifel reiterated a Buy rating and $25.00 price target as the company approaches an interim analysis of its eosinophilic esophagitis treatment. Hours later, Wedbush initiated coverage with an Outperform rating and a $17.00 price target. Broader markets were weaker, making this a purely company-specific rally.

  • The Drug Works by Injecting Steroids Directly Where It Hurts — and the Data So Far Looks Clean. EP-104GI is injected directly into the affected tissues of the esophagus to reduce inflammation with stable, localized, and long-duration drug delivery, while minimizing unwanted systemic side effects often associated with steroid treatments. In earlier trial stages, the drug reduced moderate to severe painful swallowing from 62% to 25% at 52 weeks , and 31 patients have been treated with no drug-related serious adverse events across over 230 patient-months of follow-up. That safety profile is what Wall Street is pricing in.

  • The Make-or-Break Data Readout Is Weeks Away. The Phase 2b portion, a randomized placebo-controlled study, is currently recruiting, with interim data expected in Q4 2026. This is the first time results will be measured against a placebo — the gold standard for proving a drug actually works. Wedbush sees downside risk to around $5 per share if efficacy falls below steroid competitor benchmarks at the Q4 readout , but upside into the mid-$20s should efficacy approach biologics benchmarks. That's a binary bet — the stock could nearly triple or get cut in half.

  • The Market Eupraxia Is Chasing Is Exploding. Eosinophilic esophagitis is a chronic inflammatory condition that makes swallowing painful. The global EoE market was estimated at $477.7 million in 2025 and is expected to grow at a 31.8% annual rate through 2035.

Dupixent, a biologic injection costing tens of thousands per year, currently dominates the U.S. EoE market. Eupraxia's single-dose injection approach could undercut biologics on convenience and cost — if Phase 2b data holds.

  • Cash Isn't a Worry — Yet. Eupraxia completed a $63.2 million public offering earlier this year and is well-capitalized into the second half of 2028.

Eleven analysts have a consensus "Strong Buy" with an average target of $16.35 — roughly 82% above today's price. But consensus means nothing if the placebo-controlled data disappoints. Investors buying at $9 are betting the science survives its toughest test yet.